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Gastroenterology & Hepatology: Open Access

Case Report: Methemoglobinemia Caused by Benzocain
Spray – A Warning for Surgeons
Case report

Abstract
Methemoglobinemia due to topical Benzocaine spray is an entity that has
been well described in the literature, however it is quite uncommon. Many
physicians use benzocain spray for patient comfort during and after several
procedures, the most common being Transesophageal Echocardiography, Upper
Endoscopy, Bronchoscopy, and Nasogastric Tube Placement. This condition
is a potentially catastrophic one, especially if not considered, and diagnosed
late. Methemoglobinemia should be considered in any patient who has oxygen
resistant cyanosis, or an oxygen “saturation gap” between pulse oximetry and
arterial blood gas, particularly if they are known to have had exposure to one
of the substances that cause the condition. Herein we present a case of acquired
methemoglobinemia, and a discussion of the pathophysiology, diagnosis and
treatment.
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Introduction
Methemoglobinemia is a condition whereby there is an
increase in the fraction of methemoglobin in the red blood cells.
The normal state of hemoglobin contains the iron molecule in the
divalent ferrous state. Methemoglobin results from the oxidation
of ferrous iron to a trivalent ferric iron. Methemoglobin cannot
bind and carry oxygen. The outcome of this is a functional hypoxia
due to the decreased oxygen carrying capacity of the red blood
cells. Also, the remaining heme groups, which do not have the
oxidized iron have an increased binding affinity for oxygen [1,2].
Therefore they do not release oxygen as easily at the tissue
level and cause tissue hypoxia. As red blood cells are constantly
exposed to oxidizing agents methemoglobin is formed at a rate
of about three percent per day. Several physiologic mechanisms
reduce it to deoxyhemoglobin. These pathways include the
cytochrome b5, nicotinamide adenine dinucleotide (NADH),
ascorbic acid, glucose-6-phosphate dehydrogenase (G6PD), and
glutathione reduction enzyme systems. Under normal physiologic
circumstances these mechanisms maintain equilibrium where the
methemoglobin level is less than one percent [2].

Acquired Methemoglobinemia can be caused by a host
of substances. Most commonly it is reported after the use of
oropharyngeal topical anesthetic sprays such as Benzocaine,
Lidocaine, and Prilocaine; Benzocaine is by far the most
common. This results in elevated methemoglobin by direct
or indirect oxidation of the hemoglobin [3]. Patients with
methemoglobinemia may present with headaches, lack of energy,
increased heart rate, shortness of breath, or light headedness.
Signs that are present include cyanosis, dark brown discoloration
of the blood, and low pulse oximetry in the presence of normal
arterial blood gas readings [2,4]. Symptomatology has been
correlated with methemoglobin levels. Levels in the ten percent to
twenty-five percent range show cyanosis. Levels from thirty-five
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percent to forty percent cause headache, fatigue, dizziness and
dyspnea. Levels of sixty percent can lead to arrhythmias, seizures,
lethargy, and stupor. Levels greater than seventy percent have
been associated with vascular collapse and death [5].

Treatment is generally begins with discontinuation of the
offending agent. Not all acquired methemoglobinemia requires
additional treatment. Usually if the methemoglobin level is
lest then twenty percent and the patient is asymptomatic, no
treatment is required. Generally if the methemoglobin level is
greater than thirty percent, or there is cyanosis or respiratory or
cardiac distress, the patient should be treated [5,6]. In the most
severe cases, exchange transfusion or hyperbaric oxygen has
been used with anecdotal success [6]. The treatment of choice
for most cases is Methylene Blue, it provides an artificial electron
transporter to aid in the reduction of methemoglobin. It is given
in a dose of 1-2 mg/kg IV over five minutes [1]. Risks associated
with Methylene Blue are as follows: Overdoses occur with doses
larger than seven mg/kg, which can be cumulative from multiple
administrations. Overdose can lead to dyspnea, chest pain, and
hemolysis in certain individuals [7,8]. In patients with G6PD
deficiency, Methylene Blue will likely be ineffective, and may lead
to hemolysis [9].

Case Presentation

Our patient is an eighty-one year old female who presented
with an adhesive small bowel obstruction. She was admitted to the
hospital and had a short course of non-operative management. She
continued to be obstipated and the decision was made to proceed
to surgery. She underwent an abdominal exploration, and lysis of
adhesions. Post operatively she had a nasogastric tube in place;
she was given Benzocaine 20% spray topically for discomfort
from the tube. After two applications she began to exhibit signs
of cyanosis and her pulse oximetry reading fell to eighty-two
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percent, she had no respiratory difficulties. An arterial blood gas
was obtained and the saturation was ninety-seven percent, at
this time a methemoglobin level was obtained and it was 22%.
The patient received 1mg/kg of Methylene Blue IV, six hours
Table 1: Patient response to treatment.

after this her cyanosis was gone, her saturation was 94% and her
methemoglobin level was 8%, an additional methemoglobin level
was obtained six hours later and it was three percent (Table 1).

Methemoglobin Level (%)

Pulse Oximetry (%)

Arterial Blood Gas O2 Saturation (%)

Cyanosis

Methylene Blue given

22

82

97

Yes

1mg/kg

3

96

97

No

8

Discussion

94

Methemoglobinemia is a potentially fatal condition that is
acquired due to an adverse reaction to a medication. Prior to
this event our group used topical benzocaine spray as needed for
anyone with any oriopharyngeal discomfort, and routinely for
anyone with a nasogastric tube. Methemoglobinemia is extremely
rare and the vast majority of patients who receive benzocaine
spray will not develop this condition, however one must have a
high index of suspicion in order to avoid delay in treatment and
possibly a devastating outcome.
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